Melbourne, Australia and Dresden, Germany, Jan. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”). Telix will add Therapeia’s ACD-101 theranostic program for glioblastoma to its pipeline of advanced theranostic radiopharmaceutical products. Telix also has secured the option to acquire Therapeia under pre-agreed terms. The full press release can be found here.